Clinical trial
A Non-interventional Study Evaluating Ravulizumab Treatment Outcomes in Polish Patients With Atypical Hemolytic Uremic Syndrome
NCT07399730 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Non-interventional Study Evaluating Ravulizumab Treatment Outcomes in Polish Patients With Atypical Hemolytic Uremic Syndrome
- Lead sponsor
- AstraZeneca
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- June 24, 2026
- Completion date
- September 30, 2029
- Enrollment
- 80 (estimated)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.